Anixa Biosciences, Inc. (ANIX)

NASDAQ: ANIX · Real-Time Price · USD
2.775
+0.025 (0.91%)
Apr 17, 2025, 4:00 PM EDT - Market closed
0.91%
Market Cap 87.57M
Revenue (ttm) n/a
Net Income (ttm) -12.48M
Shares Out 32.19M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,009
Open 2.760
Previous Close 2.750
Day's Range 2.760 - 2.775
52-Week Range 2.070 - 4.200
Beta 0.52
Analysts Strong Buy
Price Target 9.00 (+224.32%)
Earnings Date Jun 3, 2025

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the develo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 1, 1987
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ANIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 224.32% from the latest price.

Price Target
$9.0
(224.32% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

SAN JOSE, Calif. , April 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...

6 days ago - PRNewsWire

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach SAN JOSE, Calif. , April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechno...

11 days ago - PRNewsWire

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

SAN JOSE, Calif. , April 1, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

19 days ago - PRNewsWire

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif. , March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANI...

26 days ago - PRNewsWire

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

SAN JOSE, Calif. , March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...

27 days ago - PRNewsWire

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

SAN JOSE, Calif. , March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...

4 weeks ago - PRNewsWire

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

SAN JOSE, Calif. , March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...

5 weeks ago - PRNewsWire

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

SAN JOSE, Calif. , March 3, 2025 /PRNewswire/ -- Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced...

6 weeks ago - PRNewsWire

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

SAN JOSE, Calif. , Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

7 weeks ago - PRNewsWire

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

SAN JOSE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

7 weeks ago - PRNewsWire

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

SAN JOSE, Calif. , Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is ...

7 weeks ago - PRNewsWire

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif. , Feb. 18, 2025 /PRNewswire/ --  Anixa Biosciences, Inc. ...

2 months ago - PRNewsWire

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

SAN JOSE, Calif. , Feb. 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

2 months ago - PRNewsWire

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

SAN JOSE, Calif. , Feb. 11, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

2 months ago - PRNewsWire

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

SAN JOSE, Calif. , Feb. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...

2 months ago - PRNewsWire

Anixa Biosciences CEO Provides Letter to Shareholders

SAN JOSE, Calif. , Jan. 21, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today pro...

3 months ago - PRNewsWire

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

SAN JOSE, Calif , Dec. 4, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced t...

4 months ago - PRNewsWire

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

SAN JOSE, Calif. , Nov. 22, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

5 months ago - PRNewsWire

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA...

5 months ago - PRNewsWire

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in ...

5 months ago - PRNewsWire

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...

5 months ago - PRNewsWire

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

SAN JOSE, Calif. , Oct. 31, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

6 months ago - PRNewsWire

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

6 months ago - PRNewsWire

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif. , Oct. 15, 2024 /PRNewswir...

6 months ago - PRNewsWire

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

SAN JOSE, Calif. , Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...

6 months ago - PRNewsWire